The Alcoholic Hepatitis drugs in development market research report provides comprehensive information on the therapeutics under development for Alcoholic Hepatitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Alcoholic Hepatitis. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Alcoholic Hepatitis and features dormant and discontinued products.
GlobalData tracks 18 drugs in development for Alcoholic Hepatitis by 18 companies/universities/institutes. The top development phase for Alcoholic Hepatitis is preclinical with eight drugs in that stage. The Alcoholic Hepatitis pipeline has 17 drugs in development by companies and one by universities/ institutes. Some of the companies in the Alcoholic Hepatitis pipeline products market are: UMass Chan Medical School, Odan Laboratories and Evive Biotech.
The key targets in the Alcoholic Hepatitis pipeline products market include Telomerase Reverse Transcriptase, Toll Like Receptor 4, and Peroxisome Proliferator Activated Receptor Delta.
The key mechanisms of action in the Alcoholic Hepatitis pipeline product include Calcineurin Inhibitor with one drug in Phase I. The Alcoholic Hepatitis pipeline products include eight routes of administration with the top ROA being Intravenous and nine key molecule types in the Alcoholic Hepatitis pipeline products market including Small Molecule, and Oligonucleotide.
Alcoholic Hepatitis overview
Alcoholic hepatitis is inflammation of the liver caused by excessive alcohol consumption over a long period of time. Symptoms include changes in appetite, dry mouth, weight loss, yellowing of the skin or eyes (jaundice), fever, and fatigue. Risk factors include alcohol use, obesity, and genetic factors. Treatment includes corticosteroids and liver transplant.
For a complete picture of Alcoholic Hepatitis’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
